Intelligence · Clinical Development
Pipeline search results
Programs matching “sodium chloride” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 38 pipeline programs matching "sodium chloride" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
0.9% Sodium Chloride Solution, Glenzocimab
Pari Pharma GmbH
Acute ischemic stroke
1 trial -
0.9% Sodium Chloride, JNJ-78901563
Xian-Janssen Pharmaceutical
Invasive Extraintestinal Pathogenic Escherichia coli Disease
1 trial -
0.9% sodium chloride, GB-0895
Generate Biomedicines
severe uncontrolled asthma
1 trial -
0.9% sodium chloride, Lepodisiran
Eli Lilly Co.
Atherosclerotic Cardiovascular Disease Elevated lp(a)
1 trial -
SODIUM CHLORIDE , CAEL-101
Alexion Europe SAS
Stage IIIb cardiac AL amyloidosis
1 trial -
SODIUM CHLORIDE , CAEL-101
Alexion Europe SAS
stage IIIa cardiac AL amyloidosis
1 trial -
SODIUM CHLORIDE , DYNE-101
Dyne Therapeutics
Myotonic Dystrophy Type 1
1 trial -
SODIUM CHLORIDE, ROPIVACAINE
Pari Pharma GmbH
Cancer surgery
1 trial -
0.9% Sodium Chloride Injection
GlaxoSmithKline
Non-alcoholic Fatty Liver Disease
1 trial -
0.9% Sodium Chloride Injection, mRNA-3705
Moderna Biotech Spain
Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
1 trial -
0.9% Sodium chloride - inhalation solution
Arrowhead Pharmaceuticals Ireland Limited
Inflammatory Lung Disease
1 trial -
0.9% sodium chloride
The First People's Hospital of Lianyungang
Kidney Disease, Chronic
1 trial -
0.9% sodium chloride aqueous solution for IV infusion
Chiesi Farmaceutici S.p.A
Idiopathic pulmonary fibrosis (IPF)
1 trial -
0.9% sodium chloride, GADOTERIC ACID
Eli Lilly Co.
Relapsing Multiple Sclerosis
1 trial -
ENTR-601-44, SODIUM CHLORIDE
Entrada Therapeutics
Duchenne Muscular Dystrophy
1 trial -
Eltrekibart, 0.9% sodium chloride
Eli Lilly Co.
Moderate to Severe Hidradenitis Suppurativa
1 trial -
LAD328, SODIUM CHLORIDE
Almirall, S.A.
moderate-to-severe hidradenitis suppurativa
1 trial -
Locally Sourced 0.9% Sodium Chloride
GlaxoSmithKline
Dermatitis, Atopic
1 trial -
Locally Sourced 0.9% Sodium Chloride
GlaxoSmithKline
Dermatitis, Atopic
1 trial -
NKTR-358, Sodium Chloride 0.9% solution
Nektar Therapeutics UK Limited
Atopic Dermatitis
1 trial -
SAB-142, SODIUM CHLORIDE
SAB Biotherapeutics
Type 1 Diabetes
1 trial -
SODIUM CHLORIDE
Lacuna Pharma Pty Ltd
Idiopathic Pulmonary Fibrosis
1 trial -
SODIUM CHLORIDE , DII235
Novartis Pharmaceuticals
Cardiovascular risk reduction in participants with elevated Lp(a)
1 trial -
SODIUM CHLORIDE SOLUTION 0.9%
Lacuna Pharma Pty Ltd
Acute Ischemic Stroke
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.